Solifenacin

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Overactive Bladder

Conditions

Overactive Bladder

Trial Timeline

Jul 1, 2012 → Aug 1, 2014

NCT ID

NCT01642277

About Solifenacin

Solifenacin is a phase 2 stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT01642277. Target conditions include Overactive Bladder.

What happened to similar drugs?

10 of 20 similar drugs in Overactive Bladder were approved

Approved (10) Terminated (1) Active (9)

✅mirabegron + solifenacinAstellas PharmaApproved

✅Mirabegron + PlaceboAstellas PharmaApproved

✅SolifenacinAstellas PharmaApproved

🔄Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3

🔄solifenacin succinateAstellas PharmaPhase 3

✅SolifenacinAstellas PharmaApproved

✅Mirabegron + Tolterodine ERAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02087098	Pre-clinical	Completed	Jun 1, 2014	Mar 1, 2016	Urinary Bladder, Overactive
NCT01642277	Phase 2	Completed	Jul 1, 2012	Aug 1, 2014	Overactive Bladder
NCT01559389	Approved	Completed	Mar 9, 2012	Jun 29, 2017	Urge Urinary Incontinence
NCT01314781	Approved	Completed	Jan 1, 2012	Mar 1, 2015	Overactive Bladder
NCT01799902	Pre-clinical	Completed	Dec 1, 2011	Oct 1, 2013	Lower Urinary Tract Predominant Storage Symptoms
NCT01505439	Approved	Completed	Jun 1, 2011	Jun 1, 2014	Stress Urinary Incontinence
NCT01318837	Approved	Completed	Apr 1, 2010	Sep 1, 2011	Over Active Bladder
NCT02667470	Approved	Completed	Sep 1, 2009	May 1, 2013	Overactive Bladder
NCT01122563	Pre-clinical	Completed	Sep 1, 2009	Jan 1, 2011	Overactive Bladder
NCT00985387	Pre-clinical	Completed	Aug 1, 2009	Aug 1, 2011	Urinary Bladder, Overactive
NCT00979472	Approved	Completed	Apr 1, 2009	Jun 1, 2010	Urinary Bladder, Overactive
NCT00884104	Approved	Completed	Mar 1, 2009	Dec 1, 2010	Overactive Bladder
NCT00852696	Pre-clinical	Terminated	Feb 1, 2008	Feb 1, 2010	Overactive Bladder

Competing Products

20 competing products in Overactive Bladder

See all competitors

Product	Company	Stage	Hype Score
mirabegron + solifenacin	Astellas Pharma	Approved	43
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin	Astellas Pharma	Approved	43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine	Astellas Pharma	Phase 3	40
solifenacin succinate	Astellas Pharma	Phase 3	40
Solifenacin	Astellas Pharma	Pre-clinical	26
Betanis	Astellas Pharma	Pre-clinical	26
Solifenacin	Astellas Pharma	Approved	43
Mirabegron + Tolterodine ER	Astellas Pharma	Approved	43
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine	Astellas Pharma	Pre-clinical	26
Alpha blocker + placebo + solifenacin	Astellas Pharma	Approved	43
warfarin + YM178	Astellas Pharma	Phase 1	29
Solifenacin succinate	Astellas Pharma	Phase 3	40
solifenacin succinate + tolterodine	Astellas Pharma	Phase 3	40
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsule	Astellas Pharma	Approved	43
Solifenacin succinate	Astellas Pharma	Approved	43
Mirabegron + Placebo	Astellas Pharma	Phase 3	32
Solifenacin	Astellas Pharma	Pre-clinical	26
Solifenacin succinate + Tolterodine	Astellas Pharma	Phase 3	40
Solifenacin succinate + Placebo	Astellas Pharma	Phase 3	40